Actions
  • shareshare
  • link
  • cite
  • add
add
auto_awesome_motion View all 2 versions
Publication . Article . 2009

Adverse effects of anticancer agents that target the VEGF pathway

Helen X. Chen; Jessica N. Cleck;
Open Access
Published: 07 Jul 2009
Publisher: Zenodo
Abstract

Antiangiogenic agents that target the VEGF pathway have become an important part of standard therapy in multiple cancer indications. Although most adverse effects of VEGF inhibitors are modest and manageable, some are associated with serious and life-threatening consequences. This Review examines the toxicity profiles of anti-VEGF monoclonal antibodies and small-molecule inhibitors and considers the potential mechanisms of the adverse effects, risk factors, and the implications for patient management. Antiangiogenesis agents that target the VEGF/VEGF receptor pathway have become an important part of standard therapy in multiple cancer indications. With expanded clinical experience with this class of agents has come the increasing recognition of the diverse adverse effects related to disturbance of VEGF-dependent physiological functions and homeostasis in the cardiovascular and renal systems, as well as wound healing and tissue repair. Although most adverse effects of VEGF inhibitors are modest and manageable, some are associated with serious and life-threatening consequences, particularly in high-risk patients and in certain clinical settings. This Review examines the toxicity profiles of anti-VEGF antibodies and small-molecule inhibitors. The potential mechanisms of the adverse effects, risk factors, and the implications for selection of patients and management are discussed.

Subjects by Vocabulary

Microsoft Academic Graph classification: Pharmacology Monoclonal Adverse effect Bioinformatics Sorafenib medicine.drug medicine business.industry business Sunitinib Toxicity Vegf pathway Bevacizumab Monoclonal antibody medicine.drug_class

Subjects

Oncology

Related Organizations
Download fromView all 3 sources
lock_open
Nature Reviews Clinical Oncology
Article
License: cc0
Providers: UnpayWall
moresidebar